Ignite Creation Date:
2024-05-06 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 2:26 PM
Study NCT ID:
NCT05266846
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2022-02-18
Brief Title:
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5ALK
Sponsor:
Hunan Province Tumor Hospital
Organization:
Hunan Province Tumor Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-29
Start Date Type:
ACTUAL
Primary Completion Date:
2026-11-16
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-02-16
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-18
First Submit QC Date:
March 1 2022
Study First Post Date:
2022-03-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-28
Last Update Post Date:
2024-05-30
Last Update Post Date Type:
ACTUAL